TRAD CHI MED (00570) News

Hong Kong Stock Market Movement | China Traditional Chinese Medicine (00570.HK) Drops Over 7% After Profit Warning; H1 Loss Estimated at RMB 800 Million to RMB 850 Million Due to Business Model Impact Leading to Goodwill Impairment

China Traditional Chinese Medicine (00570.HK) fell more than 7% following its profit warning; as of the time of writing, it was down 4% at HK$1.44, with a turnover of HK$307.697 million.

Zhitong FinanceJul 20 11:17

Change of Chairman at China Traditional Chinese Medicine Holdings Co., Ltd. (HKEX: 00570)

China Traditional Chinese Medicine Holdings Co., Ltd. (HKEX: 00570) announced that its board of directors resolved on Friday (17th) that Yang Jun has resigned as Executive Director and Chairman of the Board with immediate effect due to reaching the statutory retirement age, and Guo Jinhong has been appointed as his successor.

AASTOCKSJul 20 09:42

China Traditional Chinese Medicine 1H 2025 Loss Was CNY141.76M>0570.HK

Dow JonesJul 20 06:18

China Traditional Chinese Medicine Holdings (00570.HK) issues profit warning; expects a loss of approximately RMB 800 million to RMB 850 million for the first half of the year.

China Traditional Chinese Medicine Holdings Co., Ltd. (HKEX: 00570) announced that the Group expects a loss of approximately RMB 800 million to RMB 850 million for the six months ended June 30, 2026, compared to a loss of approximately RMB 142 million for the same period last year.

Zhitong FinanceJul 17 21:35

中國中藥：內幕消息盈利預警

HKEXJul 17 21:25 · Announcements

Hong Kong-listed traditional Chinese medicine stocks strengthened, with Luye Pharma rising more than 6%.

Gelonghui, July 13 | Traditional Chinese medicine-related stocks in the Hong Kong market rose collectively, with Weiyuantang up 12%, Luye Pharma gaining over 6%, China Traditional Chinese Medicine and Tongrentang Technology rising more than 2%, and Tongrentang International, Shennongweiyao, Kangchen Pharmaceutical, and Baiyunshan all increasing by over 1%.

Gelonghui FinanceJul 13 10:39

Biopharmaceuticals: Innovation-driven industry trends are clear, with international expansion and commercial insurance offering breakthrough opportunities.

In the short term, healthcare cost containment and anti-corruption efforts in the medical sector have exerted some impact on healthcare demand, while innovative payment models, commercial insurance formularies, and off-hospital care settings may drive industry improvements. Although geopolitical tensions and shifts in liquidity have triggered a temporary pullback in the innovative drug sector and related industries, the long-term trends of innovation and international expansion remain clear, and the current correction presents medium- to long-term investment opportunities. In the second half of 2026, we continue to recommend a barbell strategy: one end focused on innovation and internationalization opportunities, and the other anchored by traditional, stable dividend-paying assets. The development trajectory of the innovative drug industry chain is clear, and order trends in the pharmaceutical supply chain remain robust. Despite short-term pressures on the innovative drug sector stemming from macroeconomic co

CICC InsightsJul 1 10:08

China TCM Sets June 2026 AGM to Vote on Board and Auditor Reappointment

TipRanksMay 29 17:17

What cyclical recovery opportunities remain at present?

According to a report by Guolian Minsheng, the core of a turnaround from distress lies in the dual resonance between the 'financial reporting cycle' and the 'industry life cycle.' In terms of sector distribution, the 22 selected industries are primarily concentrated in four major sectors: cyclicals (polyurethane, raw materials supply chain services, coking coal), manufacturing (inverters, photovoltaic cells and modules, defense electronics), consumer goods (refrigerators and washing machines, footwear and headwear, traditional Chinese medicine, active pharmaceutical ingredients, etc.), and TMT (optical components, display panels, etc.).

wallstreetcnMay 25 17:25

H-share Announcements | China Jinmao achieved a cumulative contracted sales amount of 31.234 billion yuan in the first four months, representing a year-on-year increase of 23.44%.

Tuya Inc reported a net profit of US$15.8 million in the first quarter, representing a year-on-year increase of 43.2%. Revenue from its AI business grew by 16.9%, emerging as a new growth driver. China Jinmao achieved cumulative contracted sales of RMB31.234 billion in the first four months, marking a year-on-year increase of 23.44%.

Zhitong FinanceMay 12 09:05

China Traditional Chinese Medicine (00570.HK): The 3.1 category of ancient classic formula compound preparations, Shaoyao Gancao Tang Granules and Taohex Qi Tang Granules, have been approved for market launch.

Gelonghui, May 11th: China Traditional Chinese Medicine (00570.HK) announced that two subsidiaries of the company, Sinopharm Group Guangdong Global Pharmaceutical Co., Ltd. and Guangdong Yifang Pharmaceutical Co., Ltd., have independently developed compound formulations of classical traditional Chinese medicine prescriptions classified as Type 3.1 – Shaoyao Gancao Tang Granules and Taohex Chengqi Tang Granules. These products have recently been granted drug registration certificates by the National Medical Products Administration of China and have been officially approved for market launch. The prescription for Shaoyao Gancao Tang Granules originates from the Treatise on Cold Damage Disorders authored by Zhang Zhongjing during the Eastern Han Dynasty. Modern clinical studies have demonstrated that Shaoyao Gancao Tang has significant therapeutic effects on conditions such as neck, shoulder, waist, and leg pain, gastrointestinal diseases, neurological disorders, and dermatological conditions.

Gelonghui FinanceMay 11 18:02

TRAD CHI MED: Annual Report 2025

HKEXApr 28 18:16 · Announcements

Eighteen regions, including Beijing and Shanghai, have been approved to carry out pilot programs for the integrated development of traditional Chinese medicine service consumption and trade in services.

The Ministry of Commerce and the National Administration of Traditional Chinese Medicine, among six departments, are organizing and implementing a pilot program titled "Originating from China, Benefiting the World: Integrated Development of Traditional Chinese Medicine (TCM) Service Consumption and Trade." Eighteen regions have been identified as pilot areas for the integrated development of TCM service consumption and trade. These regions include Beijing, Shanghai, Tianjin, Chongqing, Chengdu, Zhejiang, Shandong, Guangdong, and Hainan, among other provinces and cities. According to the work plan, over the next three years, these pilot areas will take the lead in experimenting with various initiatives such as TCM cultural exchange, promotion of TCM tourism routes, TCM health and wellness services, dietary therapy services, and TCM sports services. The aim is to align with the multi-layered demands of the international health and wellness market.

AASTOCKSApr 28 07:06

Trump takes action on pharmaceuticals! Import drugs face a maximum tax rate of 100%.

Trump fulfilled his threat by imposing a tariff of up to 100% on certain imported patented drugs. However, giants such as Merck and Eli Lilly and Co had already privately 'negotiated for exemptions.' Who will ultimately bear the brunt?

Golden10 DataApr 3 07:59

Stock Movement | China Traditional Chinese Medicine (00570) fell over 4% post-results, reporting an annual loss of 458 million yuan, shifting from profit to loss year-on-year.

China Traditional Chinese Medicine (00570) fell more than 4% after its earnings report. As of press time, it dropped by 3.72%, trading at HKD 1.81, with a turnover of HKD 31.219 million.

Zhitong FinanceMar 23 10:56

China Traditional Chinese Medicine (00570.HK) reported a full-year loss of RMB 342 million, reversing from a profit to a loss.

China Traditional Chinese Medicine (00570.HK) announced its 2025 annual results, with revenue of RMB 14.745 billion (hereinafter the same), representing a year-on-year decrease of 10.7%. The company reported a loss of RMB 342 million, compared to a net profit of RMB 54.07 million in the previous year, transitioning from profit to loss; basic loss per share was RMB 0.0679. No final dividend was declared.

AASTOCKSMar 22 16:54

TRAD CHI MED: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED 31 DECEMBER 2025

HKEXMar 20 22:23 · Announcements

TRAD CHI MED: DATE OF BOARD MEETING

HKEXMar 10 16:30 · Announcements

Intelligent Stock Connect Proportion Anomaly Statistics | February 11

Abnormal Fluctuation Statistics of HK Stock Connect | February 10, 2026

Zhitong FinanceFeb 11 08:36

H-share volatility | Rise in traditional Chinese medicine stocks; China TCM once surged over 8% following the announcement of favorable policies for the traditional Chinese medicine industry.

Gelonghui, February 6th | Traditional Chinese medicine stocks in the Hong Kong stock market showed strong performance at the opening of trading. Specifically, China National Pharmaceutical Group once surged over 8%, but has since pulled back to a 3% increase. Wai Yuen Tong increased by 5.8%, Tong Ren Tang Chinese Medicine and Fosen Pharmaceutical rose over 1%. Baiyun Mountain, Tong Ren Tang Technology, and Jilin Changlong Pharmaceutical also followed with gains. This follows news that the Ministry of Industry and Information Technology and seven other departments jointly issued the 'Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)'. Among the stated goals, by 2030, a preliminary collaborative development system for the entire traditional Chinese medicine industrial chain will be formed, the ability to ensure a continuous and stable supply of key traditional Chinese medicine raw materials will be further enhanced, and there will be significant improvemen

Gelonghui FinanceFeb 6 10:04